AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) saw unusually-high trading volume on Wednesday . Approximately 7,870,129 shares were traded during mid-day trading, an increase of 42% from the previous session’s volume of 5,547,270 shares.The stock last traded at $3.94 and had previously closed at $3.73.

AVEO has been the subject of a number of research analyst reports. Zacks Investment Research raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Monday, July 24th. Piper Jaffray Companies raised their price target on AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, August 28th. FBR & Co reaffirmed an “outperform” rating and issued a $3.00 price target on shares of AVEO Pharmaceuticals in a research note on Thursday, July 13th. BidaskClub raised AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 16th. Finally, ValuEngine raised AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 24th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. AVEO Pharmaceuticals currently has an average rating of “Buy” and an average target price of $3.42.

The company has a 50 day moving average price of $3.56 and a 200 day moving average price of $1.89. The firm’s market capitalization is $466.13 million.

A number of institutional investors have recently made changes to their positions in the business. Cannell Peter B & Co. Inc. grew its position in AVEO Pharmaceuticals by 22.9% in the 2nd quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 20,500 shares during the last quarter. Fore Research & Management LP bought a new position in AVEO Pharmaceuticals in the 2nd quarter valued at $111,000. Clear Harbor Asset Management LLC bought a new position in AVEO Pharmaceuticals in the 2nd quarter valued at $289,000. Paloma Partners Management Co bought a new position in AVEO Pharmaceuticals in the 1st quarter valued at $184,000. Finally, UBS Oconnor LLC bought a new position in AVEO Pharmaceuticals in the 1st quarter valued at $291,000. 53.76% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/aveo-pharmaceuticals-inc-aveo-sees-strong-trading-volume/1608673.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.